Medtronic reported a resilient Q4 2025, with revenue of $8.93 billion, up 12.8% year-over-year and 7.7% quarter-over-quarter, driven by broad-based demand across core portfolios including Cardiovascular and Diabetes. Gross margin stood at approximately 65.0%, contributing to an operating margin of 16.1% and EBITDA of $1.436 billion. Net income totaled $1.058 billion, translating to earnings per share of $0.82. Cash flow remained robust, with operating cash flow of $2.528 billion and free cash flow of $2.069 billion. The company returned capital to shareholders via dividends of $0.897 billion and share repurchases of $0.274 billion, while investing $0.459 billion in capital expenditures. The balance sheet remains solid, with total assets of ~$91.7 billion and substantial liquidity (cash and short-term investments of ~$8.97 billion). On the leverage side, net debt stood at ~$26.30 billion against an approximate trailing four-quarter EBITDA of ~$8.33 billion, implying a net debt to EBITDA of around 3.2x, consistent with a high-quality medtech balance sheet. Management commentary focused on core portfolio execution, cost discipline, and the potential for digital health and remote monitoring to support long‑term growth. Notably, management did not issue numeric guidance for the next period in the provided data; investors should monitor currency headwinds, mix effects, and the cadence of new product introductions as the primary near-term risk and growth drivers.